Glabrescione B / PTCH1 Cancer Research Results

GlaB, Glabrescione B: Click to Expand ⟱
Features:
Glabrescione B (GlaB) was extracted and purified from seeds of Derris glabrescens (Leguminosae)

Glabrescione B — Glabrescione B (GlaB) is a naturally occurring isoflavone-derived small molecule originally isolated from the seeds of Derris glabrescens. It is classified as a direct GLI transcription-factor inhibitor and experimental Hedgehog-pathway antagonist. Unlike clinically used Smoothened inhibitors, GlaB acts downstream of SMO by binding the zinc-finger DNA-binding region of GLI1 and disrupting GLI1-DNA interaction. This downstream mechanism is potentially relevant to tumors with canonical or non-canonical GLI1 activation and to resistance mechanisms that bypass SMO. GlaB remains an experimental preclinical compound rather than an approved anticancer drug.

Primary mechanisms (ranked):

  1. Direct inhibition of GLI1-DNA binding, suppressing GLI1-dependent transcription.
  2. Suppression of oncogenic Hedgehog-GLI signaling and downstream HH target-gene expression, including GLI1 and PTCH1.
  3. Suppression of cancer stem-cell self-renewal and clonogenicity in Hedgehog-dependent tumor models.
  4. Inhibition of tumor-cell proliferation and tumor growth in Hedgehog/GLI-dependent cancers.
  5. Induction of apoptosis in responsive GLI1-dependent tumors, demonstrated more recently in papillary renal-cell carcinoma models.
  6. Metabolic remodeling in glioma, including a paradoxical increase in glycolytic activity despite growth inhibition; this appears secondary and context-dependent rather than a core anticancer mechanism.

Bioavailability / PK relevance: Free GlaB has poor aqueous solubility and unfavorable formulation characteristics that substantially limit systemic translation. Nanocarrier approaches, including polymeric nanocapsules, self-assembling mPEG-cholane micelles, and liposomes, have been developed to improve solubility, circulation exposure, tumor delivery, and pharmacokinetics. In mouse models, micellar GlaB achieved longer systemic exposure and delivery across the blood-brain barrier; newer liposomal formulations produced higher exposure and slower elimination than free GlaB.

In-vitro vs systemic exposure relevance: Many mechanistic experiments use approximately 1–10 µM GlaB for 24–72 hours. These concentrations should not be assumed to be achievable or maintainable with unformulated systemic GlaB. The major translational issue is therefore drug delivery rather than evidence that oral or conventional systemic dosing can reproduce standard in-vitro concentrations. Nanocarrier formulation materially changes this exposure constraint.

Clinical evidence status: Preclinical only. Antitumor activity has been demonstrated in cultured cells, cancer stem-cell assays, xenografts, orthotopic medulloblastoma models, patient-derived renal cancer organoids, and other animal models. No human therapeutic trial of Glabrescione B and no FDA, EMA, or Health Canada approval were identified as of August 2026. Current development remains focused on formulation, pharmacokinetics, and preclinical validation.

Glabrescione B Cancer-Relevant Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 GLI1 DNA binding ↓ Not established Direct inhibition of GLI1 transcriptional activity Core molecular mechanism. GlaB binds the GLI1 zinc-finger region and interferes with GLI1-DNA interaction rather than inhibiting SMO upstream.
2 Hedgehog GLI signaling ↓ Not established Suppression of oncogenic HH transcription Downstream GLI inhibition may retain activity where GLI1 is activated independently of canonical SMO signaling.
3 GLI1 and PTCH1 target expression ↓ Not established Reduced HH target-gene transcription GLI1 itself participates in positive pathway feedback; reduced GLI1 and PTCH1 expression are useful pharmacodynamic indicators of HH-GLI suppression.
4 Cancer stem-cell self-renewal ↓ Not established Reduced stemness and tumor-propagating capacity Reduced self-renewal and clonogenicity have been demonstrated in HH-dependent tumor-derived stem-cell populations.
5 Cell proliferation and tumor growth ↓ ↔ (model-dependent) Antiproliferative and antitumor activity Observed in BCC, medulloblastoma, glioma and more recently GLI1-dependent renal cancer models. Selectivity depends strongly on pathway dependence.
6 Apoptosis ↑ (context-dependent) ↔ (model-dependent) Programmed tumor-cell death Recent papillary renal-cell carcinoma xenografts showed increased cleaved caspase-3 following GLI1 inhibition with GlaB, particularly in STK38-high tumors.
7 STK38 GLI1 positive-feedback axis ↓ (context-dependent) Not established Disruption of GLI1-driven tumor plasticity In papillary renal-cell carcinoma, GLI1 transcriptionally promotes STK38 while STK38 stabilizes HH-GLI signaling; GlaB interrupts the downstream GLI1 component of this loop.
8 Glycolytic metabolism ↑ (context-dependent) Not established Compensatory metabolic remodeling Glioma studies reported increased glucose consumption and lactate production despite inhibition of proliferation. This is a paradoxical secondary response and should not be interpreted as glycolysis inhibition.
9 Clinical Translation Constraint Poor free-drug exposure Formulation-dependent toxicity Delivery and pharmacokinetic limitation Poor aqueous solubility is a major limitation. Polymeric nanocapsules, micelles and liposomes improve solubility, circulation exposure, tumor delivery and, in CNS models, blood-brain barrier delivery. Human PK and safety remain unknown.


PTCH1, 12-transmembrane cell surface receptor Patched1: Click to Expand ⟱
Source: CGL-Driver
Type: TSG Gene
When not bound by Hh ligands, PTCH1 restrains the activity of Smo. The protein functions as a receptor protein for sonic hedgehog, desert hedgehog, and indian hedgehog proteins.
PTCH1 (Patched 1) is a gene that plays a crucial role in the Hedgehog signaling pathway, which is important for cell growth, differentiation, and tissue patterning during embryonic development. Mutations in the PTCH1 gene are associated with several types of cancer.

PTCH1 and PTCH2 act as tumor suppressors by maintaining control over Hedgehog signaling. Their loss—whether by mutation or reduced expression—leads to unchecked pathway activation, supporting cell proliferation and survival. Such abnormalities are associated with a more aggressive tumor phenotype and poorer clinical outcomes in cancers where the Hedgehog pathway is a driver of tumorigenesis.
Scientific Papers found: Click to Expand⟱
31- GlaB,    Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors
- in-vitro, BCC, NA
HH↓, Gli1↓, PTCH1↓, CSCs↓,
32- GlaB,    Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors
- in-vivo, MB, NA
HH↓, Gli1↓, PTCH1↓, TumCG↓, CSCs↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 2,   Gli1↓, 2,   HH↓, 2,   PTCH1↓, 2,   TumCG↓, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PTCH1, 12-transmembrane cell surface receptor Patched1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:90  Target#:266  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page